Ocuphire Pharma Investor Day Presentation Deck
DR
DME
21
Safety Summary From Phase 1 and Phase 2 Studies
Low AEs Across 11 Trials, <5% Mild Drug Related AES, Discontinuations Similar Across Arms
Integrated Overall Summary of Adverse Events in Eisai Phase 2 Studies (Hepatitis)
n (%)
40 (16.9%)
39 (16.5%)
APX3330 20-240 mg
(N=236)
Rash/Pruritis (mild)
1 (0.4%)
10 (4.3%)
Diarrhea/Soft Stool (mild)
# events
52
50
Any event
Mild or Moderate adverse
Events
Serious adverse events
Adverse events leading to
discontinuation
% = proportion of subjects relative to N, where n = number of subjects with an event and N = the number of subjects in the enrolled population.
Note: This table was generated by Eisai which has slightly different event and sample size counts than the Ocuphire analysis. Ocuphire will be creating an
integrated safety database. The overall conclusions between the Eisai and Ocuphire analyses are the same.
Phase 1 and Phase 2 Clinical Trials performed by Eisai and Apexian
2
16
Totals Across ALL Phase 1 and Phase 2 Studies
(Among Healthy Subjects, Hepatitis Patients, and Oncology Patients)
APX3330
Placebo
n (%)
11 (16.2%)
9 (13.2%)
14/346 (4%)
14/346 (4%)
Placebo
(N=68)
2 (2.9%)
5 (7.4%)
2/95 (2%)
# events
15
13
1/95 (1%)
2
7
***
Ocuphire
PHARMAView entire presentation